HONG KONG, Jun 13, 2025 - (ACN Newswire via SeaPRwire.com) - Tat Hong Equipment Service Co., Ltd. (“Tat Hong” or the “Company”, together with its subsidiaries, the “Group”) (Stock Code: 2153), the first foreign-owned tower crane service provider established in the PRC, has announced its annual results for the year ended 31 March 2025 (“FY2025” or the “Year”).In FY2025, the Group recorded revenue of approximately RMB 634.6 million (2024: RMB682.3 million). Loss attributable to equity holders of the Company for the year ended 31 March 2025 amounted to RMB 120.5 million (2024: RMB95.6 million). The increase in loss was primarily due to (i) slower economic growth and a downturn in the construction industry led to a decline in revenue; and (ii) the adjustment of deferred tax resulted in increased income tax expenses.As at 31 March 2025, the Group is managing a total of 1,180 tower cranes. The Group’s total tonne metres (TM) in use decreased from 3,178,404 for the year ended 31 March 2024 to 3,137,910 for the year ended 31 March 2025. As at 31 March 2025, the Group had 256 projects in progress with a total outstanding contract value of approximately RMB 721.4 million and 38 projects on hand of total expected contract value at approximately RMB 78.7 million.During the financial year, under the effect of insufficient market demand and the decline in the average monthly service price of tower cranes per TM, the supply and demand mismatch had resulted in high market competition in the entire construction machinery industry. To cope with the sluggish market conditions, the Group has developed tailored strategies and continuously adjusted its business mix, progressively reducing the revenue contribution from the real estate sector.In response to the national initiative to vigorously develop clean energy and aligning with market trends and growth potential, the Group has concentrated on thermal power projects and nuclear power projects. Clean energy projects usually entail lengthy construction cycles and large-scale operations, and the Group has obtained significant advantages by leveraging its extensive industry experience, established construction expertise, and strong technical capabilities.In FY2025, the Group accelerated its overseas market presence, thoroughly implemented its operational strategies through its subsidiaries in the Greater Bay Area and in Indonesia, and gradually expanded its fleet of large and medium-sized tower cranes. Up to now, large-tonnage-meter tower cranes have been predominantly deployed in the projects across Hong Kong and Indonesia. In light of the above, clean energy and overseas projects remain the Group’s key priorities for future development.During the year, the Group had continued the investment in the digitalization of the management platform and the research and development of new tower crane technical solutions. As at 31 March 2025, the Group possess 187 registered patents for utility models and inventions relating to tower cranes. The robust technical capabilities will continue to enable the Group to procure projects, and the enhancement in the research and development capabilities for tower crane technical solutions will reinforce the excellent delivery in services.Mr. Sean Yau, CEO of Tat Hong Equipment Service Co., Ltd., said: " In addition to the downturn in the property market and the construction industry, the geopolitical tensions and the depreciation pressure on the RMB further weakened the economy of the PRC. Tackling these economic challenges and the changing business environment., we have promptly adopted adjustments to our development strategies, including the expansion to the clean energy construction segment and the geographical expansion to the Greater Bay Area and Indonesia, and we believe the positive impact will be reflected in the coming years.Mr. Roland Ng, Chairman of Tat Hong Equipment Service Co., Ltd., said: “In the most trying circumstances, we remain steadfast in our original mission. Guided by our core corporate values ‘Virtue , Safety and Excellence , we will continue to excel in our business endeavors. In the coming financial year, we will continue to further strength our position in the above new segments and locations, and seize new opportunities in the market, so as to concentrate on the research and development of new tower crane technologies to equip ourselves with the most robust technical capabilities to deliver excellent services to our clients. Furthermore, we will also continue to achieve resources sharing, cost reduction and efficiency enhancement. With all the above measures, we believe we can fulfil the Group’s goal to become ‘the best construction equipment service provider’ in the industry.”About Tat Hong Equipment Service Co., Ltd. (Stock Code: 2153)Tat Hong Equipment Service Co., Ltd. is the first foreign-owned tower crane service provider established in the PRC. Since 2007, the Group has established as a tower crane service provider for one-stop tower crane solution services from consultation, technical design, commissioning, construction to after-sales services primarily to Chinese Special-tier and Tier-1 EPC contractors. Guided by its core values, “Virtue, Safety and Excellence”, the Group has successfully established its market position and maintained stable, reputable and loyal customer base in the construction industry in the PRC.Media EnquiriesStrategic Financial Relations LimitedHeidi SoTel:(852) 2864 4826Email: heidi.so@sprg.com.hk Mel LaiTel:(852) 2864 4855Email: mel.lai@sprg.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Jun 13, 2025 - (ACN Newswire via SeaPRwire.com) - With the national strategy of “new quality productive forces” driving high-quality development, Yee Hop Holdings Limited (“Yee Hop Holdings”; stock code: 1662.HK) subsidiary Absolute Pure EnviroSci Limited (“APEL” or “the Company”) is actively aligning with national policies. It has recently established a Microfactory in collaboration with the Hong Kong Productivity Council (“HKPC”) to industrialize the patented Wisepura Aquapura porous silica capsule technology in Hong Kong, promoting smart manufacturing and new industrialization. The HKPC’s Life & Health Tech Hall, which opened in March this year, showcases over 20 research achievements and innovative applications developed by the HKPC, InnoHK, local universities, and industry partners, including the patented Wisepura Aquapura porous silica capsule technology.The World’s First Wisepura Aquapura Microfactory Fully OperationalAs a significant achievement of the collaboration, the world’s first Wisepura Aquapura Microfactory, developed in collaboration between APEL and HKPC, was officially launched on 13 June 2025 in Kowloon Bay, Hong Kong. This marks the successful implementation of the first phase of “Industry 4.0” and a significant milestone in the industrialization of APEL’s research achievements. During the inauguration ceremony, attended by numerous guests from the investment and business sectors, Mr. Jackin Jim, Chairman of Yee Hop Holdings, Dr. David Chung, Chairman of APEL, and Dr. Pat Yeung, Director of APEL, jointly unveiled the Microfactory, officially announcing its commencement of operations.Dr. Pat Yeung, Director of APEL (first from the left), Mr. Jackin Jim, Chairman of Yee Hop Holdings (second from the left), Mr. Mohamed Butt, Executive Director of HKPC (second from the right), and Dr. David Chung, Chairman of APEL (first from the right) are pictured together at the Wisepura Aquapura Microfactory Inauguration Ceremony.Dr. David Chung, Chairman of APEL, said, “We are honored to collaborate with HKPC in establishing the Wisepura Aquapura Microfactory, and we would like to extend our heartfelt gratitude to HKPC for their support. This collaboration highlights our strong research and innovation capabilities in the field of life and health technology. The official commencement of production at the APEL Wisepura Aquapura Microfactory enhances our ability to meet the growing market demand and injects new momentum into the company’s development. Looking ahead, we will continue to expand our network of partners and actively pursue international opportunities, endeavoring to bring local research achievements to the global stage and contribute to global health and environmental protection, working together for a sustainable future.”Dr. David Chung, Chairman of APEL, delivers a speech at the inauguration ceremony.Establishes Strategic Partnership with Shanhu Group to Explore New Opportunities in Water Purification and Aquaculture Technology in the Greater Bay AreaGuangdong Shanhu Group Co., Ltd. (“Shanhu Group”), a global leader in indoor air environment solutions, has seen its core product, industrial fans, gain widespread popularity across six continents, serving over 50 million users. Since 2015, Shanhu Mechanical and Engineering Co., Ltd., a subsidiary of Shanhu Group, has taken a forward-looking approach in the research and development (R&D) of intelligent and energy-saving technologies for aquaculture machinery. On 13 June 2025, APEL officially signed a strategic Memorandum of Understanding (MoU) with Shanhu Group to jointly enter the water purification and intelligent aquaculture sectors. The collaboration aims to develop advanced solutions for high-demand applications such as water purification equipment, ecological restoration technologies, and smart monitoring systems. These innovations will target environmental projects including river remediation, black and odorous water treatment, and ecosystem rehabilitation. Additionally, the partnership will address the stable demand for new filtration materials, water treatment processes, and water quality monitoring technologies in municipal wastewater treatment plants and industrial park facilities. The two companies will also establish cooperative relationships with government environmental agencies and municipal engineering firms to participate in wastewater treatment project bids and provide customized solutions.The collaboration encompasses technological R&D, market expansion, and resource sharing. The two parties will jointly develop intelligent water quality monitoring systems, leveraging big data and artificial intelligence (AI) to optimize aquaculture decision-making while promoting high-efficiency purification technologies for environmental engineering and municipal wastewater treatment markets. The project will integrate Shanhu Group's expertise in electromechanical equipment and disinfection technologies with APEL's proprietary Wisepura Aquapura Microfactory water treatment solutions. This one-year agreement, renewable upon expiration, will initially focus on deploying the collaborative achievements in the Guangdong-Hong Kong-Macao Greater Bay Area through business and technical exchange forums. The partnership is expected to drive the advancement of environmental protection and aquaculture industries in the region, fostering industrial chain transformation. Looking ahead, the collaboration aims to gradually expand into overseas markets.APEL (left) and Shanhu Group sign a strategic Memorandum of Understanding.Advancing towards a new era of “Industry 4.0” with smart manufacturingIn advancing “Industry 4.0” initiative, the APEL Wisepura Aquapura Microfactory integrates cutting-edge technologies such as physical AI, the Internet of Things, and big data into its manufacturing processes. This enables smart monitoring and automated management, enhancing overall operational efficiency and product quality. To mitigate the impact of rapid temperature increase during mixing on the structural integrity and performance of the smart silica capsules, the factory has installed a customized smart temperature control system powered by physical AI to ensure stable product quality. The factory is also equipped with a human-machine interface (HMI), programmable logic controllers (PLCs), and clean-in-place (CIP) systems to boost production efficiency and flexibility. Additionally, it features an Industrial Internet of Things (IIoT) monitoring system to track change of temperature and volume and electricity usage in real time, optimizing energy management. It also adopts just-in-time (JIT) production management to reduce inventory backlog and resource waste, comprehensively promoting efficient smart manufacturing operations.By implementing lean management and the principles of smart manufacturing, APEL’s world-first Wisepura Aquapura Microfactory successfully integrates customized production technology, mechanical automation, and data visualization within a limited space. This achievement enables flexible small-batch customized production and achievies “Industry 4.0 1i Maturity,” paving the way for physical AI applications.Guests visiting the APEL Wisepura Aquapura Microfactory.Dual Advancement in Health and Environmental Technology InnovationWater is an essential resource for sustaining human life and ecological health. However, urban development has exacerbated water pollution, posing significant threats to public health and ecosystems. To address these challenges, APEL has developed Wisepura Aquapura, featuring the world’s first patented porous silica capsule technology. This innovation has received gold and silver medals at the International Exhibition of Inventions of Geneva in 2022 and 2024, respectively. It intelligently releases active ingredients upon contact with water, effectively eliminating over 95% of harmful microorganisms and antibiotic-resistant bacteria while also meeting diverse application needs. This technology has been widely applied across Hong Kong’s public infrastructure, targeting over 30 types of bacteria, fungi, and viruses in water supply, air conditioning, and sewage systems—including Legionella, hand-foot-and-mouth disease pathogens, influenza virus, and Candida albicans—significantly reducing the risk of waterborne and aerosol-transmitted diseases. Moreover, the silica capsule can be reused multiple times and safely disposed of at the end of its lifecycle, thereby minimizing environmental impact and setting a new standard for water treatment solutions.APEL’s world-first Wisepura Aquapura Microfactory successfully integrates customized production technology, mechanical automation, and data visualization, achieving “Industry 4.0 1i Maturity.”About Wisepura Aquapura MicrofactoryLocated in Kowloon Bay, the APEL Wisepura Aquapura Microfactory scales up laboratory processes to pilot production while effectively adapting to the spatial constraints of traditional multi-story industrial buildings in Hong Kong. It achieves a high production capacity of 6 tons per day. At the heart of the production line is its C-shaped layout, laying a solid foundation for efficient operations. The factory is equipped with mixing, filling, and screw capping systems, along with smart technologies, and a customized pipeline system that connects 5 pharmaceutical-grade mixing tanks, enabling comprehensive lean management. Due to the limited space, the factory is equipped with a 2.5-meter-high automatic capping machine that maximizes vertical space, demonstrating the perfect integration of space efficiency and smart technology.The launch of the Microfactory not only significantly enhances production efficiency but also accelerates APEL’s collaboration with Superpower Pumping Engineering Co., Ltd., facilitating the market expansion of research products. Furthermore, the Microfactory has received official orders from the Drainage Services Department, demonstrating strong recognition of its solutions and generating tangible economic benefits for the Company. To tap into the Japanese market, which places high value on personal health and environmental hygiene, APEL is currently holding an innovative interactive exhibition at The Lab. in Osaka to showcase its three flagship products—Wisepura water and air purification systems, GERMAGIC™ antimicrobial coating, and GERMAGIC™ PET health care solutions for pets—seizing growth opportunities in Asia’s health technology industry.About Yee Hop Holdings LimitedYee Hop Holdings Limited (stock code: 1662.HK) is a company listed on the Main Board of the Stock Exchange of Hong Kong Limited and a long established contractor in Hong Kong, principally engaged in the provision of foundation works and tunneling works. In addition, its associate company, Windmill Street Development, is engaged in the development of premium property projects in Birmingham, the United Kingdom. In 2023, the Group established Absolute Pure EnviroSci Limited (“APEL”), which focuses on health and environmental innovations, including the distribution and research and development of specialty biochemical and biomedical products. APEL has also established laboratories in collaboration with The Hong Kong University of Science and Technology (“HKUST”) and the Hong Kong Science Park successively. The joint laboratory, “HKUST-AP EnviroSci Ltd. Joint Laboratory on Health and Environmental Innovation,” was officially launched on 10 January 2024. Additionally, the “APEL Biomedical Technology Innovation and Translational Commercial Laboratory” located at the Hong Kong Science Park was officially inaugurated on 13 March 2024.For more information about Yee Hop Holdings, please visit: http://www.yee-hop.com.hk/About Absolute Pure EnviroSci LimitedAbsolute Pure EnviroSci Limited (“APEL”), is an indirect non-wholly owned subsidiary of Yee Hop Holdings Limited, a company listed on the Main Board of the Stock Exchange of Hong Kong Limited (stock code: 1662.HK). With a mission to improve the quality of life and living environments, APEL is principally engaged in the research and development and commercialization of health and environmental innovations. Leveraging its Multilevel Antimicrobial Polymer (MAP-1) technology, APEL has developed specialized application formulas in four key areas: air purification in aircraft, water purification, livestock health, and eco-friendly building materials, all designed to address pressing global challenges. APEL looks forward to working with researchers and industry partners worldwide to drive further health and environmental innovations.For more information about APEL, please visit: https://apesl.com/For media inquiries, please contact:AJA (IR & Communications)Avy YuTel: +852 9500 4443Email: avy.yu@ajacapital.com.hk / info@ajacapital.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

KEY HIGHLIGHTS- Revenue up by 7.4% to HK$1,576.9 million- Profit from continuing operations rose by 43.1% to HK$300.8 million- Net gearing ratio down to 8.3% from 12.2%- Recommended Final Cash Dividend of HK5.50 Cents Per Share and Special Cash Dividend of HK6.00 Cents Per Share- Continued enrichment of pipeline through R&D and strategic in-licensing- Improved operational efficiency by enhancing capacity and optimizing production leverage efficiencyHONG KONG, Jun 13, 2025 - (ACN Newswire via SeaPRwire.com) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing, and sale of essential medicines and specialty drugs, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2025 ("FY2025" or the "Reporting Period").Building on the growth momentum of previous years, Jacobson Pharma continued to make promising progress, achieving total revenue of approximately HK$1,576.9 million during the Reporting Period, a year-on-year growth of 7.4%. Profit for the year from continuing operations increased by 43.1% to HK$300.8 million, reflecting the Group’s steadfast commitment to strategic execution and operational excellence.The Group’s financial position remains strong, providing a solid foundation for fuelling future development and dividend returns to shareholders. Bolstered by a robust business performance and persistent cost management, the Group achieved an adjusted EBITDA of HK$572.8 million. Net gearing ratio improved to 8.3% from 12.2% at the close of FY2025, and cash reserves held steady at HK$509.0 million.The Board recommends the payment of a final cash dividend of HK5.50 cents per share (FY2024: HK3.00 cents per share) and a special cash dividend of HK6.00 cents per share (FY2024: Nil). Including the interim cash dividend of HK3.50 cents per share already paid, the total cash dividend for FY2025 would be HK15.00 cents per share (FY2024: HK5.50 cents per share), up by 172.7% year-on-year.Robust Portfolio Meets Rising Healthcare DemandThe Group’s sales growth in FY2025 was driven by multiple factors. Hong Kong’s extended flu season, compounded by circulating respiratory pathogens, led to a significant surge in demand for cold and flu treatments. Broader healthcare trends further supported this momentum, including an aging population, high rates of chronic conditions like diabetes and hypertension, and growing mental health needs. Additionally, public health initiatives heightened awareness of preventive care, reinforcing demand for medications and medical consultations. Together, these trends contributed to sustained sales momentum across the Group's businesses throughout the Reporting Period.The Group remains well-positioned to meet Hong Kong’s growing healthcare needs with its broad portfolio of essential medicines and specialty drugs. Backed by an efficient supply chain, it ensures reliable access to cost-effective treatment choices while reinforcing its role as a trusted healthcare service provider.Sustained R&D Momentum and Specialty Portfolio ExpansionMomentum in expanding the Group’s R&D pipeline of the Group was sustained throughout the Reporting Period, advancing its strategy to broaden the product portfolio. As of 31 March 2025, the pipeline comprised 219 products at various development stages.To expand its specialty drugs portfolio, the Group concluded various in-licensing agreements with global manufacturers for 20 high-performing products across key therapeutic areas such as immunology, oncology, cardiology, neurology, and rare diseases. Selected for their strong clinical profiles and market potential, these additions support sustained growth and reflect the Group’s commitment to advancing patient care through innovative therapies.Bringing Innovation to Enhance Patient OutcomesThe Group continues to expand market reach for Arsenic Trioxide Oral Solution, co-developed with The University of Hong Kong to treat acute promyelocytic leukaemia (APL). Clinical trials show a 97% survival rate and 100% molecular remission, earning it the Orphan Drug Designation from both the U.S. FDA and EMA. A global Phase III trial will be launched in 2026 with market approval targeted for 2028.Jacobson Pharma also achieved a significant milestone on 20 February 2025, with the launch of supply chain liaison services for Axicabtagene Ciloleucel (Yikaida) – a CAR-T therapy - in partnership with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Fosun Kairos Biotechnology Inc.. Supported by an Advanced Therapeutic Product (ATP) logistics license, this breakthrough therapy for diffuse large B-cell lymphoma marks a major advance in next-generation cancer care.Powering Growth with Smart ProductionIn line with the Groups’ strategic goal of enhancing its manufacturing capabilities, Jean Marie Pharmacal Co Limited, a member of the Group, commenced the development of a new pharmaceutical facility at Tai Po InnoPark in February 2025. Supported by the Hong Kong Government’s New Industrialisation Acceleration Scheme, the facility will house 10 smart production lines for sterile eye drops, solid dosage forms, and oral liquids. Leveraging AI, robotics, and real-time analytics, the advanced facility will boost production efficiency and quality standards. Trial production is slated for late 2026, with a focus on developing specialty products to cater to unmet medical needs. This investment strengthens the Group’s industry leadership and supports Hong Kong’s emergence as a hub for advanced pharmaceutical manufacturing.Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, stated, “FY2025 has been another eventful year for Jacobson Pharma, underscoring the strength of our strategy, the dedication of our team, and the trust of our stakeholders. These foundations continue to position us as a leading force in Hong Kong’s generic pharmaceutical sector.Looking to 2026, we remain optimistic about our prospects and growth. Healthcare policy reforms and rising medication demand from an aging population and chronic conditions will fuel the growth of the generic drugs market. With a strong pipeline, expanding partnerships, and digital innovation, we are well-positioned to seize growth opportunities and create sustainable values for the Group’s businesses”About Jacobson Pharma Corporation Limited (Stock Code: 2633)Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated and engaged in the research, development, production, sale and distribution of essential medicines and specialty drugs. As a major provider of generic drugs in Hong Kong, the Group has one of the most extensive sales and distribution coverage for both the private and public sectors in Hong Kong, with an expanding reach into strategically selected Asian markets. Carrying a broad product portfolio and taking a pre-eminent market position in a number of therapeutic categories, the Group operates a host of 9 PIC/S GMP licensed production facilities for generic drugs in Hong Kong.The Group is committed to strategically enhancing its portfolios by introducing high-value-added specialty products. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan and Cambodia, forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com Copyright 2025 ACN Newswire via SeaPRwire.com.

PIONEERTOWN, CA, June 13, 2025 - (ACN Newswire via SeaPRwire.com) - ESCAPE Records releases two transcendent works from its secretive Mojave Desert hub in Pioneertown CA: the Parallel Universe EP, a genre-defying musical odyssey from touring electronic artists and industry veterans, and Gong Song! (Live from Escape, Pioneertown CA), a 45-minute sound healing masterpiece by Alessandra Montana.Naturally Occurring Emoji - BEEPLEEveryday from BEEPLE. Cover of Parallel Universe EP. Courtesy of Escape Records LLC.Crafted where social media fades to the obscure and creativity thrives, these two new records aim to forge deep audience connections - inspiring a sense of solidarity between the creative and their audience.The Parallel Universe EP blends electronic, Americana, and Latin vibes, born during a songwriting retreat at ESCAPE's legendary studio, some 40 miles from the gates of Coachella in the high desert of California, a mile above sea level under a myriad of stars. Listeners are invited to ponder what their life would be like in a parallel universe; evoking poignant emotions in today's somewhat turbulent world.Tracks are shared by studio founder and producer ROC Gardner, Latin Grammy-nominated Cimafunk (La Vida), Jamie N Commons (Hold Me While You Wait), DJ Tennis (Life and Death), and Grammy-nominated Jan Blomqvist (Remote Control), joined by producers Joseph Ray (Nero), Daniel Cantisani, Nikko Gibler (RicoshÄ“i), and Devlin Thorn alongside artists that include Kim Bullard (Elton John) and Craig McClune (David Gray) who lent their expertise to evolving the tracks.Mixed by Mick Guzauski (Daft Punk, The Weeknd, Michael Jackson) and mastered by Bernie Grundman, tracks include Mezcalita (June 13), Happy Unhappy (June 20), La Sugar (June 27), and Never Know (July 4). BEEPLE's surreal artwork Naturally Occurring Emoji and an AI-driven video by The Dor Brothers amplify the EP's cosmic narrative."The universal sky we spent each night under sparked something raw," says ROC. "It was awesome breaking out of our channels - we got to capture all these ideas, unbound by trends or any other concerns - it was great fun!"Simultaneously, Alessandra Montana's Gong Song! (Live from Escape) captures a live 45-minute sound journey, recorded meticulously with vintage gear and microphones at ESCAPE. Guided by mixing engineer Rob Columbus and mastered by Grundman, Montana's gongs and sacred instruments weave a meditative portal for healing."Escape's magic let me share my practice globally. I can't wait for people to hear this and experience the journey we went on," says Montana.ESCAPE, a 140-acre creative haven hosting Rüfüs Du Sol, Arctic Monkeys, Usher, RAYE - and many others - fosters unfiltered artistry. The studio hopes to deliver magic - and its music - unfettered and unfiltered.Visit www.esca.pe for more.Assets: Press release, artwork, lyrics, .wav files available upon request.Interviews: info@esca.peJan Blomqvist appears courtesy of Armada Music B.V.Tracks:Mezcalita (1st Single): https://audiosalad.ffm.to/commons-roc-mezcalitaParallel Universe EP: https://audiosalad.ffm.to/parallel-universeGong Song! (Live from Escape): https://audiosalad.ffm.to/gong-songContact InformationSteven Bradley9/9 - Digital/Social Mediaescape@9slash9.comEscape RecordsLabel Contactinfo@esca.peSOURCE: Escape Records LLC Copyright 2025 ACN Newswire via SeaPRwire.com.

With the Department of Labour Peninsular Malaysia’s approval, the Ria Payroll Management System, coupled with the Ria Wallet and Prepaid Card Program, in collaboration with Mastercard, aims to promote financial inclusion among unbanked migrant workers throughout Malaysia, offering employers a secure and compliant way to manage their payroll needs.KUALA LUMPUR, June 13, 2025 - (ACN Newswire via SeaPRwire.com) - Ria Money Transfer (“Ria”), a global leader in the cross-border money transfer industry and business segment of Euronet Worldwide, Inc. (NASDAQ: EEFT) has been officially approved by the Department of Labour Peninsular Malaysia (JTKSM) for the disbursement of digital wage payments via the Ria Wallet. By streamlining wage distribution through digital means, the Ria Prepaid Card Program, in collaboration with Mastercard, provides an omni-channel solution to employers who may struggle with conventional banking access for their workforce.The Ria Wallet facilitates various financial activities such as depositing funds, withdrawing cash from ATMs, paying bills, and conducting domestic and international transfers. Customers will also be able to make payments in millions of locations in Malaysia via QR payment linked to DuitNow. In addition, the Ria Wallet streamlines payroll management for Malaysia-based companies throughout industries heavily dependent on migrant workers, including construction, agriculture, and manufacturing.According to the International Organization of Migration (“IOM”), migrants represent an estimated 15.3% of Malaysia’s total workforce, many of whom are unbanked. The Ria Wallet addresses the challenges faced by both workers and employers in the country's cash-centric payment landscape.Ria’s presence in Malaysia since 2001 has positioned Ria as one of the leading players in the money transfer industry. Leveraging its strong physical network of 624,000 locations worldwide and its presence in nearly 200 countries and territories, Ria aims to provide a diverse and seamless service experience to all customers.Espen Kristensen, Ria Money Transfer’s Managing Director Asia Pacific, expressed his excitement for the expansion of Ria's service portfolio in Malaysia. He emphasized, “We understand the challenges employers in Malaysia face when it comes to managing wages for their workers. Through the Ria Wallet, companies will be able to benefit from a digital solution that improves transparency and compliance across their operations”.In collaboration with Mastercard, The Ria Prepaid Card Program underscores the company’s commitment to driving positive social impact through the financial empowerment of different communities worldwide. About Ria Money TransferRia Money Transfer, a business segment of Euronet (NASDAQ: EEFT), delivers innovative financial services including fast, secure, and affordable global money transfers. With the world’s largest cross border real-time money movement network, Ria moves money where it matters. Bridging the gap between digital and physical spaces, Ria’s omnichannel products and services provide unprecedented consumer choice, including real-time payments, mobile wallets, currency exchange, home delivery, and cardless ATM payouts. Ria’s global infrastructure, powered by the Dandelion real-time, cross-border payments network, facilitates financial access to customers, agents and partners alike. By creating new market opportunities and promoting economic growth around the world, Ria opens ways for a better everyday life. Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE / INDIA, June 13, 2025 - (ACN Newswire via SeaPRwire.com) - Asia Research & Engagement (ARE), a leading sustainability-focused consultancy and capital markets engagement firm, has expanded its India team with two senior appointments: Shishir Soti, Director, Global Operations and Partnerships and Arun Kumar, Strategic Advisor – Power Markets and Technology Innovation.Founded in 2013 and headquartered in Singapore, ARE works across Asia’s key economies – including China, India, and Japan – to drive sustainability outcomes through the alignment of capital markets, corporate strategy, and policy. India’s expanding influence in energy, agriculture, and capital markets makes it not just a domestic focus but a regional anchor for accelerating Asia’s net-zero transition.“India is already making bold strides on its decarbonisation journey,” said Benjamin McCarron, Founder & Managing Director, ARE. “Expanding our footprint here strengthens our ability to connect investor expectations and corporate ambition across the region, from Tokyo to Bangkok to Singapore. India’s scale and innovation are pivotal to designing future-fit systems across all of Asia.”Shishir Soti brings more than 25 years of experience to ARE, having held senior positions in banking and financial services at institutions including Standard Chartered and ICICI Bank, as well as senior roles at environmental groups such as the Shakti Sustainable Energy Foundation and Environmental Defense Fund. At ARE he will help deepen the integration of India into ARE’s regional programmes on financed emissions, sustainable food systems, and transition financing. He will also spearhead stakeholder engagement and fundraising strategy for ARE’s India programmes, advancing efforts to align Indian corporates and banks with net-zero goals.“India’s ambition to reach net-zero by 2070 has implications far beyond its borders,” said Soti. “Its energy and agricultural transitions will shape supply chains, investment flows, and climate ambition throughout Asia. I’m proud to support ARE’s work connecting policy, capital, and corporate action at this critical intersection.”Arun Kumar joins ARE with more than 25 years of experience in power markets, technology, and strategy, having held leadership positions at PTC India, HSBC Securities, KPMG and CRISIL where he was consistently ranked among India’s top energy analysts. He will provide strategic insights into regulatory trends, market innovation, and grid decarbonisation.“ARE’s investor-informed approach has already helped shift conversations in China, Japan, and Southeast Asia,” said Kumar. “India’s power market is on the cusp of transformation, and I look forward to helping shape the trajectory through collaborative engagement and technology foresight.”Soti and Kumar will work closely with Rituj Sahu, Director – Protein Transition (India), who has been leading ARE’s work on food systems, climate finance, and impact stewardship in India since 2022. Their collective expertise positions ARE to deepen its regional impact across three core pillars: Energy transition and financed emissions engagement with corporates and banks; Sustainable food and agriculture systems, with a focus on the protein transition; Capital mobilisation, bridging global finance with local sustainability outcomes.The India expansion complements and strengthens ARE’s ongoing work in Singapore, China, Taiwan, Japan, and Thailand – creating a more connected and coordinated platform for sustainable transformation across Asia.“To solve regional sustainability challenges, we need local intelligence, regional coordination, and global capital alignment,” added McCarron. “India is integral to the systems change ARE is driving across the region.”About Asia Research & Engagement (ARE)Creating change through investor-backed engagement. ARE's pioneering approach fills an engagement gap to bring leading investors into dialogue with Asian-listed companies. ARE currently works with investors representing US$10trillion. ARE covers Asian-listed companies from the financial sector, energy-related industries, and food value chains, seeking to advance a sustainable and compassionate Asia.For media interviews and further enquiries, please contactWani DiwakarAsia Research & Engagement (ARE) wani.diwarkar@asiareengage.com Copyright 2025 ACN Newswire via SeaPRwire.com.

KEY HIGHLIGHTS- Revenue up by 20.7% to HK$782.3 million- Gross profit increased by 22.4% to HK$413.7 million- Consolidated profit attributable to equity shareholders grew by 51.2% to HK$197.3 million- The Board recommends a final dividend of HK11.5 cents per share- Flagship proprietary brands Ho Chai Kung, Po Chai Pills, and Flying Eagle Woodlok Oil delivered robust growth through effective brand management campaigns- Concentrated Chinese medicine granules (“CCMG”) remained resilient, providing a steady contribution to overall business performanceHONG KONG, Jun 12, 2025 - (ACN Newswire via SeaPRwire.com) - JBM (Healthcare) Limited ("JBM Healthcare" or the "Company"; Stock Code: 2161, together with its subsidiaries, the "Group"), a leading branded healthcare products marketer and distributor in Hong Kong, today announced the annual results of the Group for the year ended 31 March 2025 ("FY2025" or the "Reporting Period").Despite a lackluster retail environment in Hong Kong, JBM Healthcare delivered a robust financial and operational performance in FY2025. Revenue from the branded healthcare business rose by 20.7% year-on-year to HK$782.3 million. Gross profit grew by 22.4% to HK$413.7 million, while consolidated profit attributable to equity shareholders surged 51.2% to HK$197.3 million.This significant increase in consolidated profit attributable to equity shareholders was driven by robust sales of flagship brands - including Ho Chai Kung, Po Chai pills, and Flying Eagle Woodlok Oil, complemented by the resilient performance of its CCMG business. These strong results underscore the effective execution of the Group’s integrated sales and marketing strategies, and its strategic foresight in capturing growth opportunities in the branded consumer healthcare market across Hong Kong, Macau, and major cities in the Greater Bay Area.The Board recommends a final dividend of HK11.5 cents per share. Including the interim dividend of HK5.5 cents per share already paid, the total dividend for FY2025 will be HK17.0 cents per share.Solid Performance Across Core SegmentsIn the branded medicines business, sales revenue recorded strong growth of 43.2%, propelled by Ho Chai Kung’s sustained market momentum. Ho Chai Kung successfully expanded its market penetration through precisely targeted marketing initiatives that broadened its consumer base while simultaneously reinforcing brand recognition.Sales in the proprietary Chinese medicines segment grew by 5.0% against the backdrop of softened local retail sentiment of Chinese medicines and herbs, driven by the momentum of flagship brands Po Chai Pills and Flying Eagle Woodlok Oil, alongside the resilient performance of the CCMG business. Po Chai Pills enhanced brand visibility through sustained TVC placements and title sponsorship of popular television programs. Meanwhile, Flying Eagle Woodlok Oil reinforced its market position with an integrated campaign themed “Flying Eagle – The Real Master’s Choice”, highlighted by a viral “Flying Eagle Bro” billboard at Tsim Sha Tsui Star Ferry Pier, which tripled brand awareness.In the health and wellness products segment, revenue increased by 44.9%, driven by the steady growth of Oncotype DX Breast Recurrence Score Test (“Oncotype DX”), along with the expansion of our product portfolio and enhanced marketing efforts to meet consumer healthcare demands of the mass market. Oncotype DX has gained increasing recognition among healthcare professionals in Hong Kong and Macau.Capturing the Growth Potential of Cross-Border E-Commerce and TCM SectorThe Group has made steady progress in expanding its online presence on cross-border e-commerce platforms as well as strategically positioned to capitalise on the growing traditional Chinese medicine (“TCM”) sector in Hong Kong and the Greater Bay Area. The Group’s flagship stores on Tmall Global and JD.com have performed strongly, with Ho Chai Kung ranking among the top 10 overseas medicines during the 2024 Double 11 sales event. To drive sustainable growth, the Group is also diversifying into new categories while enhancing both its B2B and B2C sales networks.Strategic Acquisition of Tin Hee TongIn April 2025, the Group completed the acquisition of a 90% stake in Tin Hee Tong Medicine Factory, Limited, whose flagship product, Tin Hee Tong Tin Hee Pills, is a well-recognised brand in Hong Kong and mainland China, particularly among female consumers for its efficacy in regulating the menstrual cycle and supporting reproductive health. The acquisition expands the Group’s proprietary Chinese medicine portfolio and creates synergies by integrating Tin Hee Tong’s brand with the Group’s manufacturing and marketing strengths. Leveraging its expertise in brand management, the Group will launch a comprehensive marketing campaign to boost awareness, enhance engagement, and broaden distribution.Mr. Patrick Wong, Chief Executive Officer of JBM Healthcare, commented, “Amid the challenging retail environment, we delivered strong financial and operational performance, driven by our robust portfolio, the enduring appeal of our flagship brands, and our unwavering focus on operational excellence.”“Looking ahead, we remain committed to disciplined growth and operational excellence. With rising health awareness, increasingly sedentary lifestyles, and an ageing population continuing to fuel demand, we are well-positioned to capitalise on growth opportunities in the consumer healthcare sector. We will continue to sharpen our brand management capabilities, strengthen our core brand equity, expand our product offerings, and extend our market reach.”About JBM (Healthcare) Limited (Stock Code: 2161)JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia, and other select countries. The Group is a distinctive player in the sector with marketing expertise and heritage in pharmaceuticals that prioritises product efficacy and quality to meet consumers' healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines, and health and wellness products, which include well-recognised household brands such as Po Chai Pills, Ho Chai Kung Tji Thung San, Tin Hee Tong Tin Hee Pills, Flying Eagle Woodlok Oil), Tong Tai Chung Woodlok Oil, Shiling Oil and Konsodona Medicated Oil. JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021. For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.